% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Teipel:281125,
      author       = {Teipel, Stefan J and Tang, Yi and Khachaturian, Ara},
      title        = {{S}ex differences in treatment effects of lecanemab and
                      donanemab: {A} {B}ayesian reanalysis of {CLARITY}-{AD} and
                      {TRAILBLAZER}-{ALZ}2.},
      journal      = {Alzheimer's $\&$ dementia / Translational research $\&$
                      clinical interventions},
      volume       = {11},
      number       = {3},
      issn         = {2352-8737},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-01084},
      pages        = {e70155},
      year         = {2025},
      abstract     = {This study investigated evidence for or against a
                      difference in treatment effect between women and men for
                      lecanemab and donanemab.Data were derived from supplementary
                      analyses of the regulatory studies CLARITY-AD (lecanemab)
                      and TRAILBLAZER-ALZ2 (donanemab). Bayes factor functions
                      were used to analyze treatment effects on Clinical Dementia
                      Rating Sum of Boxes (CDR-SB) scores.We found moderate
                      evidence of a lower treatment effect in women than in men
                      for lecanemab (maximum Bayes factor = 5.97), suggesting that
                      the presence of an effect was almost six times more likely
                      than the absence of an effect. For donanemab, there was
                      evidence against a treatment effect difference between women
                      and men. There was evidence of a treatment effect difference
                      between lecanemab and donanemab (maximum Bayes factor =
                      8.47) in women, but not in men.A better understanding of sex
                      differences in treatment efficacy and their causes is
                      urgently needed.Lecanemab was six times more likely to be
                      ineffective than effective in women.There was no evidence of
                      a difference between the sexes in the effect of
                      donanemab.Lecanemab and donenamb differed in treatment
                      efficacy in women but not in men.Future trials should
                      include sufficient power for sex related interaction
                      effects.},
      keywords     = {anti‐amyloid antibodies (Other) / personalized treatment
                      (Other) / prespecified secondary analysis (Other) /
                      subgroups (Other) / treatment efficacy (Other)},
      cin          = {AG Teipel},
      ddc          = {610},
      cid          = {I:(DE-2719)1510100},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40918062},
      pmc          = {pmc:PMC12412750},
      doi          = {10.1002/trc2.70155},
      url          = {https://pub.dzne.de/record/281125},
}